Clinical Research Directory
Browse clinical research sites, groups, and studies.
R.E.C.K vs Exparel in Robotic Nephrectomy
Sponsor: Wake Forest University Health Sciences
Summary
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Official title: Efficacy of Ropivacaine Epinephrine Clonidine Ketorolac (R.E.C.K) vs Exparel in Robotic Nephrectomy: a Randomized, Prospective Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
170
Start Date
2025-11-14
Completion Date
2027-10
Last Updated
2026-01-20
Healthy Volunteers
No
Interventions
Ropivacaine HCL
123 mg, intramuscular
Exparel
100 mL total dose - Intramuscular (IM), intraoperatively
Epinephrine
0.25 mg, intramuscular
Clonidine HCL
0.04 mg, intramuscular
Ketorolac
15 mg, intramuscular
Locations (1)
Levine Cancer
Charlotte, North Carolina, United States